文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

经麻醉气体保存装置吸入异氟烷与丙泊酚用于德国和斯洛文尼亚ICU有创通气患者镇静的比较:一项开放标签、3期、随机对照、非劣效性试验

Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial.
PubMed 文献 · Lancet Respir Med · 2021-08-26
一句话结论对有创通气需镇静的成人,吸入异氟烷在维持RASS -1至-4目标范围时间上非劣于丙泊酚,且阿片用量更低、清醒更快。

这项3期、开放标签、随机对照非劣效性试验在德国21个中心和斯洛文尼亚3个中心纳入338例成人有创通气患者,301例随机分配至经Sedaconda麻醉气体保存装置吸入异氟烷(n=150)或静脉丙泊酚(n=151)镇静48小时(范围42-54小时)。异氟烷组阿片剂量强度较丙泊酚组低29%,第1天自主呼吸更频繁,第2天清醒时间更短。最常见不良事件为高血压、谵妄、少尿和房颤。

要点

  • 最常见不良事件:高血压(异氟烷10例[7%] vs丙泊酚2例[1%])、谵妄(8例[5%] vs 7例[5%])、少尿(7例[5%] vs 6例[4%])、房颤(5例[3%] vs 4例[3%])。

适用人群与场景

  • 年龄≥18岁、在ICU接受有创通气的成人患者,来自德国21个中心和斯洛文尼亚3个中心。
  • 原文未提及具体的纳入标准(如预期镇静时长、疾病类型)和排除标准。

诊断标准与关键阈值

  • 主要终点评估采用Richmond Agitation-Sedation Scale(RASS),目标范围为-1至-4。
  • 非劣效性界值为15%(主要终点时间百分比差异)。
  • 主要终点在符合方案人群(per-protocol population)中评估:至少12小时镇静、5次或以上RASS测量、无重大方案违背的合格参与者。

处置流程与药物剂量

  • 第一步:筛选成人(≥18岁)有创通气需镇静患者,随机1:1分配至异氟烷吸入组或丙泊酚静脉输注组。
  • 第二步(异氟烷组):经Sedaconda麻醉气体保存装置(ACD-L死腔100 mL或ACD-S死腔50 mL)吸入异氟烷,持续48小时(范围42-54小时)。
  • 第三步(丙泊酚组):静脉输注丙泊酚(20 mg/mL),持续48小时(范围42-54小时)。
  • 第四步:以RASS -1至-4为目标范围调整镇静深度,评估RASS目标范围内时间百分比。
  • 原文未提及异氟烷的具体吸入浓度、丙泊酚的具体输注速率(mg/kg/h)及调整方案,也未提及 opioid 的具体药名、剂量、给药途径和频次(仅报告吗啡当量剂量强度)。

红旗征与不能漏的情况

  • 异氟烷组高血压发生率高于丙泊酚组(10例[7%] vs 2例[1%]),需监测血压。
  • 两组谵妄(8例[5%] vs 7例[5%])、少尿(7例[5%] vs 6例[4%])、房颤(5例[3%] vs 4例[3%])均有发生,需监测相应指标。
  • 原文未提及需要立刻处理或不能漏诊的其他红旗征及对应处理。

研究设计与关键结果

  • 研究类型:3期、随机、对照、开放标签、非劣效性试验;样本量:338例入组,301例随机分配(异氟烷n=150,丙泊酚n=151);中心数:德国21个中心+斯洛文尼亚3个中心;人群:成人(≥18岁)有创通气患者;干预:经ACD吸入异氟烷 vs 静脉丙泊酚,持续48小时(范围42-54小时)。
  • 不良事件:高血压(10例[7%] vs 2例[1%])、谵妄(8例[5%] vs 7例[5%])、少尿(7例[5%] vs 6例[4%])、房颤(5例[3%] vs 4例[3%])。

证据类型、等级与局限

  • 证据类型:3期、随机、对照、开放标签、非劣效性试验。
  • 局限:开放标签设计;仅纳入德国和斯洛文尼亚的24个中心;研究由Sedana Medical AB资助;主要终点在符合方案人群中评估(异氟烷组146例[97%]、丙泊酚组148例[98%]纳入分析);镇静时长限于48小时(范围42-54小时)。

对床旁实践的改变

  • 对于有临床镇静需求的有创通气成人患者,可考虑经麻醉气体保存装置吸入异氟烷作为丙泊酚的替代镇静方案,因主要终点显示非劣效。
  • 选择异氟烷镇静时,需预期阿片类药物需求可能降低(本研究中吗啡当量剂量强度低29%),并可能更早实现自主呼吸和清醒。
  • 使用异氟烷镇静需监测高血压等不良事件,本研究中异氟烷组高血压发生率高于丙泊酚组(7% vs 1%)。
  • 原文未提及该研究结果不适用于哪些人群(如特定疾病亚组、儿童、孕妇等)。
  • 常见陷阱:原文未提及。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号EudraCT 2016-004551-67。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Previous studies indicate that isoflurane could be useful for the sedation of patients in the intensive care unit (ICU), but prospective studies evaluating isoflurane's efficacy have been small. The aim of this study was to test whether the sedation with isoflurane was non-inferior to sedation with propofol.

METHODS: This phase 3, randomised, controlled, open-label non-inferiority trial evaluated the efficacy and safety of up to 54 h of isoflurane compared with propofol in adults (aged ≥18 years) who were invasively ventilated in ICUs in Germany (21 sites) and Slovenia (three sites). Patients were randomly assigned (1:1) to isoflurane inhalation via the Sedaconda anaesthetic conserving device (ACD; Sedana Medical AB, Danderyd, Sweden; ACD-L [dead space 100 mL] or ACD-S [dead space 50 mL]) or intravenous propofol infusion (20 mg/mL) for 48 h (range 42-54) using permuted block randomisation with a centralised electronic randomisation system. The primary endpoint was percentage of time in Richmond Agitation-Sedation Scale (RASS) range -1 to -4, assessed in eligible participants with at least 12 h sedation (the per-protocol population), five or more RASS measurements, and no major protocol violations, with a non-inferiority margin of 15%. Key secondary endpoints were opioid requirements, spontaneous breathing, time to wake-up and extubation, and adverse events. Safety was assessed in all patients who received at least one dose. The trial is complete and registered with EudraCT, 2016-004551-67.

FINDINGS: Between July 2, 2017, and Jan 12, 2020, 338 patients were enrolled and 301 (89%) were randomly assigned to isoflurane (n=150) or propofol (n=151). 146 patients (97%) in each group completed the 24-h follow-up. 146 (97%) patients in the isoflurane group and 148 (98%) of patients in the propofol group were included in the per-protocol analysis of the primary endpoint. Least-squares mean percentage of time in RASS target range was 90·7% (95% CI 86·8-94·6) for isoflurane and 91·1% (87·2-95·1) for propofol. With isoflurane sedation, opioid dose intensity was 29% lower than with propofol for the overall sedation period (0·22 [0·12-0·34] vs 0·32 [0·21-0·42] mg/kg per h morphine equivalent dose, p=0·0036) and spontaneous breathing was more frequent on day 1 (odds ratio [OR] 1·72 [1·12-2·64], generalised mixed linear model p=0·013, with estimated rates of 50% of observations with isoflurane vs 37% with propofol). Extubation times were short and median wake-up was significantly faster after isoflurane on day 2 (20 min [IQR 10-30] vs 30 min [11-120]; Cox regression p=0·0011). The most common adverse events by treatment group (isoflurane vs propofol) were: hypertension (ten [7%] of 150 vs two [1%] of 151), delirium (eight [5%] vs seven [5%]), oliguria (seven [5%] vs six [4%]), and atrial fibrillation (five [3%] vs four [3%]).

INTERPRETATION: These results support the use of isoflurane in invasively ventilated patients who have a clinical need for sedation.

FUNDING: Sedana Medical AB.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Meiser A, Volk T, Wallenborn J, et al. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. Lancet Respir Med. 2021. PMID: 34454654. doi:10.1016/S2213-2600(21)00323-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。